

## Methylprednisolone (Solu-Medrone®)

<p style="text-align: center;"><b>Potential SALAD</b> Methylprednisolone as Depo-Medrone® is <b>NOT</b> for IV administration</p>	
<b>Form</b>	Solu-Medrone® (preservative free) 500mg vial Solu-Medrone® (preservative free) 1g vial Solu-Medrone® 40mg Act-O-Vial Solu-Medrone® 125mg Act-O-Vial
<b>Reconstitution</b>	<p><b>500mg and 1g vial</b> Use diluents (WFI) provided.</p> <p><b>40mg and 125mg Act-O-Vial reconstitution</b></p> <ul style="list-style-type: none"> <li>• Press down on plastic activator to force diluent into the lower compartment.</li> <li>• Gently agitate to produce a solution.</li> <li>• Remove plastic tab.</li> <li>• Sterilise top of stopper with an alcohol swab.</li> <li>• Insert needle squarely through the centre of the plunge-stopper until the tip is just visible.</li> <li>• Invert vial and withdraw the dose.</li> </ul>
<b>Compatibility &amp; Stability</b>	Sodium Chloride 0.9% Glucose 5%
<b>Administration</b>	<p><b><u>IV Injection</u></b> Use reconstituted solution. Doses of up to 250mg may be given by slow IV injection over 5 minutes.</p> <p><b><u>IV infusion</u></b> Dilute reconstituted solution. Add doses over 250mg to 50-100mL infusion fluid and give over 30 - 60 minutes.</p>
<b>Monitoring</b>	<ul style="list-style-type: none"> <li>• Manufacturer advises monitor blood pressure and renal function (serum creatinine) routinely in patients with systemic sclerosis—increased incidence of scleroderma renal crisis.</li> <li>• Rapid IV administration of large doses is associated with cardiovascular collapse.</li> </ul>

**Information provided relates to Solu-Medrone® manufactured by Pfizer.**

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542*